Specifically, we aim to (1) evaluate the prevalence and significance of elevated anti-TPO and hsCRP levels in SCH compared to other thyroid disorder subgroups and healthy controls; (2) examine the relationship between anti-TPO and hsCRP levels and their potential interactions in driving systemic inflammation; and (3) assess the association between elevated levels of these markers and the risk of progression to overt hypothyroidism, CVD, or metabolic complications. This evidence concerns the gene TPO and thyroid gland disorder.